[¿Â¶óÀÎ] Á¦19Â÷ KSKD ±³À°¿¬¼öÁý´ãȸ
ÀϽà : 2021. 12. 1 (¼ö) ¿ÀÈÄ 6½Ã 30ºÐ -¿ÀÈÄ 8½Ã 50ºÐ
Àå¼Ò : ¿Â¶óÀÎ Zoom
µî·Ïºñ : ¹«·á
ÆòÁ¡ : ´ëÇÑÀÇ»çÇùȸ ¿¬¼öÆòÁ¡ 2Á¡
ÁÖ°ü : ´ëÇѰ¡¿Í»ç³¢º´ÇÐȸ
1. ¿Â¶óÀÎ Á¢¼Ó Àοø Á¦ÇÑÀ¸·Î ÀÎÇÏ¿© ¼±Âø¼ø µî·Ï (Àü¹®ÀÇ, 100¸í)À» ÁøÇàÇÏ°í ÆòÁ¡Àº 2Á¡ÀÔ´Ï´Ù.
2. »çÀü µî·Ï ÁÖ¼Ò: ÃßÈÄ °øÁö ¿¹Á¤ÀÔ´Ï´Ù. »çÀü µî·Ï½Ã ¾Ë·ÁÁֽŠÀ̸ÞÀÏ ÁÖ¼Ò·Î Á¢¼Ó¸µÅ©°¡ Á¦°øµË´Ï´Ù. °Á ÀÔÀå½Ã »çÀüµî·Ï½Ã ¾Ë·ÁÁֽмºÇÔÀÌ Ç¥½ÃµÉ ¼ö ÀÖµµ·Ï ÇØÁֽʽÿÀ.
3. µî·Ïºñ´Â ¹«·áÀ̳ª ±³Àç´Â ȸ¿ø °ø°£ (°Ô½ÃÆÇ)¿¡ Á¤È¸¿øÀ¸·Î ÀÔȸ ÇϽźе鿡°Ô¸¸ Á¦°øµË´Ï´Ù. ´ëÇѰ¡¿Í»ç³¢º´ÇÐȸ Á¤È¸¿ø ÀÔȸ´Â ȨÆäÀÌÁö http://www.kskd.kr °øÁö»çÇ׿¡¼ Á¤È¸¿ø Æò»ýȸºñ ¾È³»¸¦ Ŭ¸¯Çϼż ÇÏ½Ã¸é µË´Ï´Ù.
------------------------------------------------------------------------------------------
2021 ±¹Á¦ °¡¿Í»ç³¢º´ ½ÉÆ÷Áö¿ò (IKDS) ¿ä¾à
½Ã°£
|
Á¦¸ñ
|
¿¬ÀÚ
|
18:25-18:30
|
°³È¸»ç
|
¼Û¹Î¼· ȸÀå, À±°æ¸² ÇмúÀÌ»ç
|
18:30-18:45
|
Epidemiology Around the World
|
ÀÌ»óÀ± (¼¿ïÀÇ´ë ¾î¸°À̺´¿ø)
|
18:45-19:00
|
Diagnosis / Clinical Examinations
|
±è¼ºÇý (Â÷ÀÇ´ë ºÐ´çÂ÷º´¿ø)
|
19:00-19:15
|
Pathogenesis and Genetics, KD; New Approaches in Etiology
|
À±°æ¸² (°æÈñÀÇ´ë °µ¿°æÈñ´ëº´¿ø)
|
19:15-19:30
|
Animal model / immunology/Novel experiment (Basic research)
|
À̼ö¿µ (°¡Å縯ÀÇ´ë ºÎõ¼º¸ðº´¿ø)
|
19:30-19:40
|
Discussion
|
19:40-19:55
|
Acute Phase and New Therapy
|
¼Û¹Î¼· (ÀÎÁ¦ÀÇ´ë ÇØ¿î´ë¹éº´¿ø)
|
19:55-20:10
|
KD and MIS-C: Worldwide Epidemiology, Clinical Achievements
|
°ûÁöÈñ (¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø)
|
20:10-20:25
|
Cardiovascular Complications(JSKD-APSC joint session' Prospect of Asian Guidelines for CVcomplications of KD'Æ÷ÇÔ)
|
Çѹ̿µ (°æÈñÀÇ´ë °æÈñ´ëº´¿ø)
|
20:25-20:40
|
Long term management and Transition
|
Àº¿µ¹Î (¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø)
|
20:40-20:50
|
Discussion
|
20:50-20:55
|
Æóȸ»ç
|
Á¤´ëö ºÎȸÀå (°¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø)
|
- ÁÜ Âü¿©½Ã µî·ÏÇϽмºÇÔÀ¸·Î ¼öÁ¤ÇϽþî ÀÔÀå ºÎŹ µå¸³´Ï´Ù.
- ºñµð¿À off À½¼Ò°Å off ·Î ÀÔÀåÇØ ÁÖ¼Å¾ß ÇÕ´Ï´Ù. ÀÔÀå½Ã »çÀüµî·Ï½Ã ¾Ë·ÁÁֽмºÇÔÀÌ Ç¥½ÃµÉ ¼ö ÀÖµµ·Ï ÇØÁֽʽÿÀ.
- °ÀÇ Áú¹®Àº äÆÃÀ¸·Î ºÎŹ µå¸³´Ï´Ù.
- Áý´ãȸ °ü·Ã ¹®ÀÇ : office@bjsolution.co.kr
ÁøÇü¼· 010-2887-2093 (¹®ÀÚ·Î Àü´Þ ºÎŹ µå¸³´Ï´Ù) |